Skip to content

GI Cancers

EU Focus Meeting 2026


📍 Lisbon, Portugal

🗓️ September 11 - 12, 2026


Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the GI Cancers Focus Meeting 2026, to be held at on September 11 - 12, 2026.

Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing GI Cancers research and patient treatment.

This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.

 

Chairs of GI Cancers Focus Meeting 2026:

Gerald-Prager

Gerald Prager, MD
Medical University of Vienna, Austria

Michel-Ducreux

Michel Ducreux, MD
Gustave Roussy Institute, Villejuif, France


Supporters to be announced...
Interested in supporting this meeting? Get in contact:
alex.worthington@md-education.com

Agenda & Faculty

September 11, 2026 | Day 1  

September 11, 2026 | Day 1  

07:00 AM
Registration Opens
08:00 AM
Industry Supported Independent Expert Discussion
08:45 AM
Plenary Presentation: Topic TBD (ctDNA /
EO-GI Cancer)
eric-van-cutsem
Eric Van Cutsem, MD
KU Leuven, Belgium

Session I: Pancreas Cancer
Moderated by:

TBD
KOL TBD

09:05 AM
Systemic Treatment Options in mPDAC
Pascal-Hammel
Pascal Hammel, MD
Hôpital Beaujon, Clichy, France
09:25 AM
Targeting RAS
Davide-Melisi
Davide Melisi, MD
Medical School and University Hospital,
Verona, Italy
09:45 AM
Neoadjuvant Treatment Concepts in BR- and LA-PDACs
Teresa-Macarulla
Teresa Macarulla, MD
University Hospital Vall d’Hebron,
Barcelona, Spain
10:05 AM
Panel Discussion
10:25 AM

Coffee Break

Session II: Biliary Tract Cancers
Moderated by:

TBD
KOL TBD

 

10:45 AM
Stratified Treatment Concepts in Metastatic CCA
Cindy-Neuzillet
Cindy Neuzillet, MD
Institut Curie, Paris, France
11:05 AM
Neoadjuvant Treatment Approaches
Antoine-Hollebecque
Antoine Hollebecque, MD
Gustave Roussy Institute, Villejuif, France
11:25 AM
Emerging Targets in CCA
Arndt-Vogel
Arndt Vogel, MD
Hannover Medical School, Germany
11:45 AM
Panel Discussion
12:05 PM
Lunch Break + Faculty and Fellow Photo
12:55 PM
Industry Supported Independent Expert Discussion

Session III: Hepatocellular Cancer
Moderated by:

TBD
KOL TBD

 

01:40 PM
Potential Role of Immunotherapy in Earlier Stages
Bruno-Sangro
Bruno Sangro, MD
Clínica Universidad de Navarra, Spain
02:00 PM
Immunotherapy Combinations in Advanced/Met HCC
Lorenza-Rimassa
Lorenza Rimassa, MD
IRCCS Humanitas Research Hospital, Milan, Italy
02:20 PM
Sequential Treatment of mHCC
Lorenza-Rimassa
Lorenza Rimassa, MD
IRCCS Humanitas Research Hospital, Milan, Italy
02:40 PM
Panel Discussion
03:00 PM
Coffee Break
03:20 PM
Industry Supported Independent Expert Discussion

Session IV: Neuroendocrine Tumors
Moderated by:

TBD
KOL TBD

 

04:05 PM
Strategy of Treatment of NET
Marianne-Pavel
Marianne Pavel, MD
Friedrich-Alexander University of Erlangen, Germany
04:25 PM
Neuroendocrine Carcinoma Treatment
Julien-Hadoux
Julien Hadoux, MD
Gustave Roussy Institute, Villejuif, France
04:45 PM
Surgical Management of Net
Massimo-Falconi
Massimo Falconi, MDD
Università Vita-Salute San Raffaele, Milan, Italy
05:05 PM
Panel Discussion
05:25 PM
Adjourn

September 12, 2026 | Day 1  

07:00 AM
Registration Opens
08:00 AM
Industry Supported Independent Expert Discussion
07:45 AM
Coffee Break

Session V: Esophagogastric Cancer
Moderated by:

TBD
KOL TBD

 

09:05 AM
Perioperative Treatment Options of Gastric Cancer
Elizabeth-Smyth
Elizabeth Smyth, MD
University of Oxford, UK
09:25 AM
How to Stratify First-Line Treatment in mGC According to the Molecular Profile
Sylvie-Lorenzen
Sylvie Lorenzen, MD
Klinikum Rechts der Isar, Technical University Munich, Germany
09:45 AM
Emerging Treatment Concepts in GEC
Mark-Henegouwen
Mark I. van Berge
Henegouwen, MD

Amsterdam UMC, Netherlands
10:05 AM
Panel Discussion
10:25 AM
Coffee Break

Session VI: Metastatic Colorectal Cancer
Moderated by:

TBD
KOL TBD

 

10:45 AM
Plenary Presentation: Novel Treatment Approaches in mCRC
Tanios-Saab
Tanios Bekaii Saab, MD
Mayo Clinic, Phoenix, AZ
11:05 AM
IOs in dMMR/MSS mCRC
Thierry-Andre
Thierry André, MD
Hospital Saint-Antoine, Ap-Hp Sorbonne
University, Paris, France
11:25 AM
Who Still Benefits From (m)FOLFIRINOX
Chiara-Cremolini
Chiara Cremolini, MD
University of Pisa, Italy
11:45 AM
Panel Discussion
12:05 PM
Lunch Break + Faculty and Fellow Photo
12:55 PM
Industry Supported Independent Expert Discussion

Session VII: Early-Stage and Oligometastatic CRC
Moderated by:

TBD
KOL TBD

 

TBD
KOL TBD

 

01:40 PM
Organ Preservation in Rectal Cancer
Andre-dHoore
Andre d’Hoore, MD
KU Leuven, Belgium
02:00 PM
IOs Neoadjuvant or Adjuvant in Early Stage Colon Cancer?
Jenny-Seligmann
Jenny Seligmann, MD
University of Leeds, UK
02:20 PM
ctDNA Guided Adjuvant Treatment in Resected CRC
Julien-Taieb
Julien Taieb, MD
Paris Cité University, France
02:40 PM
Panel Discussion
03:00 PM
Coffee Break
03:20 PM
Industry Supported Independent Expert Discussion

Session VII: Early-Stage and Oligometastatic CRC
Moderated by:

TBD
KOL TBD

 

04:05 PM
Immunotherapy Treatment Combinations in Metastatic Anal Canal Cancers
Sheela-Rao
Sheela Rao, MD
Royal Marsden NHS Foundation Trust,
London, UK
04:25 PM
Systemic Treatment in Small Intestine Carcinoma
Thomas-Aparicio
Thomas Aparicio, MD
Assistance Publique, Hôpitaux de Paris (AP-HP), France
04:45 PM
Hereditary Syndromes in GI Cancer and How to Screen
Erika-Martinelli
Erika Martinelli, MD
Università degli Studi della Campania Luigi Vanvitelli Naples, Italy
05:05 PM
Panel Discussion
05:25 PM
Adjourn

Alex Worthington
Project Manager

How long has Alex Worthington been in the business?

Alex Worthington has been with MD Education since 2024

About Alex Worthington

As Assistant Project Manager, I work to ensure the Smooth running of events, assisting in the search process, outreach, organization, and the maintenance of any event. Having a Diverse Career background Working around the world, I pride myself on networking and creating positive relationships seamlessly with all attendees.

Alex-Worthington 2